(Q38172859)

30 August 2017

title

Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus (English)

1 reference

30 August 2017

Carl V Asche

1

1 reference

30 August 2017

Stephen E Hippler

series ordinal

2

1 reference

30 August 2017

Dean T Eurich

series ordinal

3

1 reference

30 August 2017

publication date

1 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

32

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

15-27

1 reference

https://scigraph.springernature.com/pub.10.1007/s40273-013-0117-7

30 August 2017

exact match

0 references

cites work

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Standards of medical care in diabetes--2013

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Costs and consequences associated with newer medications for glycemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0117-7

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland.

21 January 2018

1 reference

12 December 2020

Low-value services in value-based insurance design.

1 reference

12 December 2020

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

1 reference

12 December 2020

Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions

1 reference

12 December 2020

Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden

1 reference

12 December 2020

[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]

1 reference

12 December 2020

10.1007/S40273-013-0117-7

Identifiers

DOI

1 reference

30 August 2017

1 reference